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Aim

The MOMENTUM 3 pivotal trial established superiority of the HeartMate 3 (HM3) left ventricular assist device
(LVAD), a fully magnetically levitated centrifugal-flow pump, over the HeartMate II axial-flow pump. We now evaluate
HM3 LVAD outcomes in a single-arm prospective continuous access protocol (CAP) post-pivotal trial study.
.....................................................................................................................................................................
Methods
We enrolled 2200 HM3 implanted patients (515 pivotal trial and 1685 CAP patients) and compared outcomes
and results
including survival free of disabling stroke or reoperation to replace or remove a malfunctioning device (primary
composite endpoint), overall survival and major adverse events at 2 years. The 2-year primary endpoint [76.7%
vs. 74.8%; adjusted hazard ratio (HR) 0.87, 95% confidence interval (CI) 0.71–1.08, P = 0.21] and overall survival
(81.2% vs. 79.0%) were similar among CAP and pivotal cohorts despite sicker patients (more intra-aortic balloon
pump use and INTERMACS profile 1) in CAP who were more often intended for destination therapy. Survival was
similar between the CAP and pivotal trial in transplant ineligible patients (79.1% vs. 76.7%; adjusted HR 0.89, 95% CI
0.68–1.16, P = 0.38). In a pooled analysis, the 2-year primary endpoint was similar between INTERMACS profiles
1–2 (‘unstable’ advanced heart failure), profile 3 (‘stable’ on inotropic therapy), and profiles 4–7 (‘stable’ ambulatory
advanced heart failure) (75.7% vs. 77.6% vs. 72.9%, respectively). The net burden of adverse events was lower in CAP
(adjusted rate ratio 0.93, 95% CI 0.88–0.98, P = 0.006), with consequent decrease in hospitalization.
.....................................................................................................................................................................
Conclusions
The primary results of accumulating HM3 LVAD experience suggest a lower adverse event burden and similar survival
compared to the pivotal MOMENTUM 3 trial.

..........................................................................................................
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Graphical Abstract

Accumulating post-pivotal trial experience with the HeartMate 3 (HM3) left ventricular assist device (LVAD) suggests a lower adverse event burden,
reduced hospitalizations and similar survival free of disabling stroke or reoperation to replace or remove a malfunctioning pump as compared to
the pivotal MOMENTUM 3 trial outcomes at 2 years. These beneficial outcomes were noted across the continuum of clinical severity in advanced
heart failure and especially among transplant ineligible patients in whom outcomes may now compare favourably with those in transplant eligible
patients at 2 years.

..........................................................................................................
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Introduction
Ongoing engineering advances in left ventricular assist devices
(LVADs) have led to their application in advanced heart failure
patients refractory to medical therapy, with evidence of markedly
improved survival and quality of life.1 The Multicenter Study of
MagLev Technology in Patients Undergoing Mechanical Circulatory
Support Therapy With HeartMate 3 (MOMENTUM 3) randomized clinical trial demonstrated the superiority of the HeartMate
3™ (HM3) LVAD, a fully magnetically levitated centrifugal-flow
pump, compared to the HeartMate II™ LVAD, an axial-flow pump,
with respect to survival free of disabling stroke or reoperation to
replace or remove a malfunctioning device at 2 years.2–4 Whether
HM3 LVAD clinical outcomes observed within the early phase of
application during the pivotal trial can be replicated or improved
in a larger cohort as post-trial clinical experience accumulates,
remains uncertain.
Early experience with the HM3 LVAD was derived in a single-arm
50 patient study performed by experienced surgical teams and
pointed to reduced pump thrombosis and increased pump
durability.5,6 The pivotal MOMENTUM 3 trial, which included 515

...............................................................
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HM3 LVAD implanted patients, demonstrated survival outcomes
that exceeded those observed in trials or registry experiences.7,8
Other studies such as the Evaluating the HeartMate 3 with Full
MagLev Technology in a Post-Market Approval Setting (ELEVATE) registry suggested excellent 2-year survival; however, the
entry criteria were less well controlled and endpoints relied on
site-reported, non-adjudicated outcomes.9 Once the randomized
trial phase of MOMENTUM 3 was completed, a post-pivotal trial
continuous access protocol (CAP) was initiated as a single-arm
prospective study to assess the reproducibility of HM3 LVAD
outcomes among the centres. This initiative included similar entry
criteria as the pivotal trial and followed patients carefully through
2 years with independent adjudication of clinical events.10
We now present the primary 2-year outcomes of the CAP phase
of the MOMENTUM 3 trial portfolio. This report was designed
to address several objectives: (i) assess if the larger HM3 LVAD
experience is associated with reproducible or improved outcomes
by evaluating differences in the principal composite endpoint and
overall survival between the early pivotal trial experience and
the post-trial experience, (ii) determine if HM3 LVAD survival
differs by clinical severity at implant [Interagency Registry for

© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Mechanically Assisted Circulatory Support (INTERMACS) profile]
or by therapeutic goal based on transplant eligibility [destination
therapy (DT)], and (iii) outline the net burden of major adverse
events (as well as their individual components) over the course of
this clinical experience.

Methods
Device
The HM3 LVAD is a centrifugal, continuous-flow pump, with a
friction-free fully magnetically levitated rotor, wide blood flow pathways to decrease destruction of red blood cells, and an asynchronous
pulse feature using fixed speed changes, to prevent pump stasis.11 The
pump system includes the outflow graft, a modular driveline and an
external system controller. This system is intended to support the left
ventricle in those with advanced heart failure who are refractory to
optimal medical management and have a limited quality and expected
length of life.4

Patients and study conduct
The MOMENTUM 3 pivotal trial phase enrolled 1028 patients at
69 centres in the United States. Of the 516 patients randomized to
the HM3 arm, 515 underwent HM3 implantation between September
2014 to August 2016 and comprise the pivotal cohort in this analysis.
Details of the MOMENTUM 3 pivotal trial design, including detailed
inclusion/exclusion criteria, have been published previously.10 After
pivotal trial enrolment was completed, CAP enrolment was initiated
at the same sites. The study timeline for the MOMENTUM 3 pivotal
trial and CAP are shown in online supplementary Figure S1. Inclusion
and exclusion criteria for the CAP were the same as the pivotal trial.
Starting in October 2017, bridge to transplant (BTT) patients were
excluded from CAP enrolment. Shortly after the HM3 pump was
approved for long-term use in October 2018, enrolment in the CAP
cohort was closed with a total of 1685 patients. All CAP patients
had a study outcome (death, heart transplantation, HM3 removal or
permanent deactivation, or withdrawal) or reached 2 years of HM3
support by November 2020. The ‘pooled cohort’ combines the CAP
and pivotal cohorts for a total of 2200 patients.
The MOMENTUM 3 trial portfolio, including the pivotal and CAP
studies, complied with the Declaration of Helsinki. Study protocols were approved by each institutional review board, and written
informed consent was obtained from all patients or their authorized
representatives. Study follow-up for the pivotal trial occurred at day
1, day 7, initial discharge, 1, 3, 6, 12, 18, and 24 months post-HM3
implant. The CAP study did not include the 3- and 18-month follow-up
visits. The trial was sponsored by Abbott, which provided the devices,
selected the sites, and analysed the data. The primary MOMENTUM
3 trial data for the pivotal study have been previously published, and
access to its raw data was provided to an independent statistician who
validated all primary analyses.2–4 In this analysis of the complete trial
portfolio, two co-authors (J.C. and C.W.) maintained the raw data in
the study and take full responsibility for the integrity of the data and
the accuracy of the data analysis. The utilized data analysis sets were
independently validated by two statisticians assigned by the sponsor.
The first author drafted the manuscript, principally contributed to
the present study design and analysis plan, and all authors were
provided unrestricted access to any requested analyses of the data. All
authors read the manuscript, made critical suggestions to the analyses,
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assisted in the editing of the manuscript and agreed to its submission
for publication. All conflicts of interests and disclosures have been
provided for each of the authors.

Endpoints
The primary composite endpoint for the study was survival to transplant, recovery or ongoing LVAD support, free of disabling stroke or
reoperation to replace or remove a malfunctioning pump, at 2 years
post-implant. Disabling stroke was defined as a modified Rankin score
(MRS) greater than 3 (scale ranges from 0–6 representing increasing
levels of disability with 0 indicating no symptoms, 3 moderate functional
limitations and 6 being death). Other secondary endpoints included
overall survival and pump replacement. Competing outcomes of death,
heart transplantation, HM3 removal or permanent deactivation, and
withdrawal were also evaluated through 2 years. These endpoints were
compared between the pivotal and CAP cohorts.
Major
adverse
events
were
categorized
as
either
haemocompatibility-related
or
non-haemocompatibility-related
events, and these have been previously defined.2–4,12,13
Haemocompatibility-related adverse events included suspected pump
thrombosis, stroke, and bleeding.12 Non-haemocompatibility-related
adverse events included infection, right heart failure, cardiac arrhythmias, respiratory failure, and renal dysfunction. The protocol specified
definitions for each adverse event were previously published.2–4,10
An independent clinical events committee adjudicated adverse events
for bleeding, infection, neurological dysfunction, suspected device
thrombosis and haemolysis. The utilized adverse event definitions
and clinical events committee remained the same during the pivotal
trial and CAP. The index hospitalization length of stay and all-cause
rehospitalizations were evaluated in patients discharged on HM3
support from the initial implant hospitalization.
In addition to comparisons of the overall pivotal and CAP cohorts,
outcomes were analysed by the intended goal of therapy as either
BTT or bridge to candidacy (BTC) or DT between study cohorts.
To evaluate the impact of baseline clinical severity on outcomes,
INTERMACS profiles 1–2 (clinically ‘unstable’ advanced heart failure;
profile 1 includes critical cardiogenic shock, and 2 includes progressive
decline on inotropic therapy with end-organ failure) were compared to
profile 3 (clinically ‘stable’ but requiring inotropic therapy) and profiles
4–7 (clinically ‘stable’ ambulatory advanced heart failure) within the
pooled cohort.

Statistical methods
Continuous variables are presented as mean and standard deviation
and categorical variables are presented as counts and percentages.
Comparisons of baseline demographics were performed with the t-test
for continuous variables and Chi-square test for categorical variables
(Fisher’s exact test was used when Cochran’s rule was not met). For the
primary composite endpoint, event-free survival was calculated using
the Kaplan–Meier method with data censored for non-fatal outcomes
such as elective transplant or LVAD deactivation for myocardial recovery. Withdrawal after LVAD implant, death, disabling stroke, pump
replacement, urgent transplant due to pump malfunction and pump
deactivation for reasons other than myocardial recovery were failure
events. Hazard ratios (HR) were calculated with Cox proportional hazards modelling and presented with 95% confidence intervals (CI). To
account for differences in major baseline demographics, all HR were
adjusted for age, sex, race (Caucasian and non-Caucasian), intended
goal of therapy (BTT/BTC and DT), and INTERMACS profile (profiles
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1–3 and 4–7) unless otherwise specified. Adverse event rates are presented as the percentage of patients or events per patient-year (EPPY).
The overall ‘net burden’ of major adverse events was calculated by evaluating the combined EPPY rate of the haemocompatibility-related and
non-haemocompatibility-related events. All-cause readmission rates
for discharged patients are presented in EPPY. For adverse event and
readmission rate comparisons, rate ratios (RR) with 95% CI from
Poisson regression were adjusted for age, sex, race, intended use, and
INTERMACS profile. Initial length of stay is presented as median with
interquartiles (Q1–Q3) and compared with Wilcoxon rank sum test.
In order to identify independent predictors for specific adverse
events [e.g. use of a right ventricular assist device (RVAD)], multivariate
logistic regression was utilized. The final model was constructed
using stepwise selection (P-value entry <0.05, P-value stay <0.10).
All P-values are two-tailed and were considered significant if P < 0.05.
Statistical analysis was performed with SAS software, version 9.4 (SAS
Institute, Cary, NC, USA).

Results
Baseline characteristics
Baseline characteristics in the pivotal and CAP cohorts are shown
in Table 1. Demographics including age, body size, sex, race,
and ischaemic aetiology of heart failure were similar between
groups. Due to the exclusion of BTT patients (after commercial
approval of the HM3) midway through CAP enrolment, a higher
number of DT patients entered in the CAP vs. pivotal cohorts
(75.6% vs. 61.6%, P < 0.001). In addition, there was a greater
prevalence of intra-aortic balloon pump (IABP) use (16.7% vs.
12.4%, P = 0.019) and predominance of ‘crashing and burning’
INTERMACS profiles 1 (4.1% vs. 2.1%, P = 0.036) in CAP compared to the pivotal trial. Other parameters also indicate that
the CAP cohort was sicker than the pivotal cohort with worse
renal function and reduced use of renin–angiotensin–aldosterone
antagonists and beta-blockers (likely due to increased intolerance). There was a lower haematocrit and higher white blood
cell count, consistent with increased illness severity in the
CAP cohort. The use of cardiac resynchronization therapy was
lower in CAP.

Primary composite endpoint and overall
survival
Kaplan–Meier estimates of survival free of disabling stroke or reoperation to replace or remove a malfunctioning pump are shown in
Figure 1A. At 2 years post-implant, a similar proportion of patients
in the CAP vs. pivotal cohorts achieved the composite endpoint
[76.7% vs. 74.8%; adjusted HR 0.87 (95% CI 0.71–1.08), P = 0.21].
Online supplementary Figure S2 shows the pump replacement component of the composite endpoint. Pump exchange rates were low
in both cohorts with 98.4% of the CAP cohort and 96.9% of the
pivotal cohort being free of pump replacement at 2 years [adjusted
HR 0.53 (95% CI 0.25–1.10), P = 0.09]. In the pivotal cohort, 12
pump exchanges were performed for driveline damage or electrical faults (n = 4), suspected device thrombosis or elevated lactate
dehydrogenase (n = 3), outflow graft twist (n = 2), infection (n = 1),

........................................................................................................................................................................
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Table 1 Comparison of baseline characteristics
between the pivotal and continued access protocol
cohorts
Baseline variable

Pivotal
CAP cohort
P-value*
cohort
(n = 1685)
(n = 515)
.........................................................................
Age, years
BSA, m2
BMI, kg/m2
Male sex
Caucasian
Ischaemic aetiology of
heart failure
Intended use
Destination therapy
Bridge to transplant
Bridge to candidacy
Bridge to recovery
Rescue therapy
IABP
INTERMACS profile
1
2
3
4–7
Diabetes
Prior stroke
ACE inhibitor or ARB
Beta-blocker
Inotropes
CRT
CABG
Cardiac index, L/min/m2
RAP, mmHg
PCWP, mmHg
PAPI
RVSWI, mmHg mL/m2
Total bilirubin, mg/dL
BUN, mg/dL
Creatinine, mg/dL
eGFR, mL/min/1.73 m2
Haematocrit, %
WBC count, 103 /mL

59.2 ± 12.4
2.07 ± 0.27
29.2 ± 6.3
410 (79.6%)
341 (66.2%)
216 (41.9%)

59.9 ± 12.2
2.08 ± 0.29
29.1 ± 6.7
1342 (79.6%)
1135 (67.4%)
760 (45.1%)

0.22
0.86
0.84
0.99
0.60
0.21

317 (61.6%)
112 (21.7%)
86 (16.7%)
0 (0%)
0 (0%)
64 (12.4%)

1274 (75.6%)
173 (10.3%)
233 (13.8%)
4 (0.2%)
1 (0.1%)
282 (16.7%)

<0.001
<0.001
0.11
0.58
1.00
0.019

11 (2.1%)
156 (30.4%)
272 (52.9%)
75 (14.6%)
233 (45.2%)
50 (9.7%)
158 (30.7%)
284 (55.1%)
444 (86.2%)
188 (36.5%)
102 (19.8%)
1.96 ± 0.52
10.8 ± 6.5
23.1 ± 8.6
4.14 ± 4.91
561 ± 260
1.00 ± 0.55
28.3 ± 14.0
1.35 ± 0.43
61.5 ± 23.8
36.5 ± 5.6
7.66 ± 2.55

69 (4.1%)
517 (31.0%)
843 (50.5%)
241 (14.3%)
690 (40.9%)
128 (7.6%)
338 (20.1%)
668 (39.6%)
1474 (87.5%)
407 (24.2%)
320 (19.0%)
1.99 ± 0.59
11.1 ± 8.3
23.4 ± 8.9
3.82 ± 4.37
569 ± 295
1.04 ± 0.56
29.4 ± 15.4
1.39 ± 0.42
58.8 ± 22.8
35.9 ± 5.6
7.95 ± 2.89

0.036
0.79
0.33
0.88
0.08
0.12
<0.001
<0.001
0.45
<0.001
0.68
0.24
0.34
0.57
0.19
0.60
0.10
0.12
0.08
0.024
0.027
0.034

ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BMI, body mass
index; BSA, body surface area; BUN, blood urea nitrogen; CABG, coronary artery bypass graft;
CAP, continued access protocol; CRT, cardiac resynchronization therapy; eGFR, estimated
glomerular filtration rate; IABP, intra-aortic balloon pump; PAPI, pulmonary artery pulsatility
index; PCWP, pulmonary capillary wedge pressure; RAP, right atrial pressure; RVSWI, right
ventricular stroke work index; WBC, white blood cell.
*P-values from Chi-square or Fisher’s exact test for categorical variable comparisons and t-test
for continuous variable comparisons.

and other reasons (n = 2). In the CAP cohort, there were 20 pumps
replaced due to infection (n = 7), outflow graft twist (n = 5), suspected pump thrombosis (n = 2), driveline electrical fault (n = 1),
and other reasons (n = 5). Overall rates of outflow graft twist
obstruction (including those treated with or without pump replacement) were similar between the pivotal cohort (1.6%, n = 8) and
the CAP cohort (1.8%, n = 30).
Overall survival rates at 2 years are shown in Figure 1B. In the
CAP cohort, survival was 81.2% compared to 79.0% in the pivotal
cohort. After controlling for major baseline demographics between
the cohorts, the adjusted HR for CAP vs. pivotal cohorts was
0.84 (95% CI 0.67–1.06) (P = 0.15). In Figure 2, survival was also
similar between the CAP and pivotal trial within BTT/BTC patients

© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Composite endpoint and overall survival. Comparison of (A) survival free of disabling stroke or reoperation to replace or remove

[adjusted HR 0.70 (95% CI 0.43–1.14), P = 0.15] and DT patients
[adjusted HR 0.89 (95% CI 0.68–1.16), P = 0.38].

Competing outcomes
Online supplementary Figure S3 shows the cumulative rates of
study outcomes in the CAP and pivotal cohorts. The transplant
rate was lower compared to the pivotal cohort (16% vs. 23%)
and the proportion of patients ongoing on HM3 support was
subsequently higher in CAP at 2 years (64% vs. 56%), likely due
to the higher number of DT patients in the CAP cohort.

Impact of clinical severity at implant
and outcomes
In Figure 3, the primary composite endpoint and survival are compared between clinical severity profiles that included INTERMACS
profiles 1–2, 3 and 4–7. All groups performed similarly with
respect to the composite endpoint. Survival at 2 years was better
in INTERMACS profile 3 compared to profiles 1–2 [adjusted HR
0.77 (95% CI 0.62–0.96), P = 0.022].

Adverse events
The overall net burden of adverse events (Figure 4) was significantly
better in CAP [adjusted RR 0.93 (95% CI 0.88–0.98), P = 0.006].
This improvement was driven primarily by a decrease in the
frequency of non-haemocompatibility-related events [adjusted
RR 0.88 (95% CI 0.82–0.93), P < 0.001]. To account for potential bias resulting from a higher transplant rate in the pivotal
cohort, rate comparisons between cohorts were also adjusted for
transplant occurrence for either haemocompatibility-related
events [adjusted RR 1.09 (95% CI 0.99–1.20), P = 0.09]
or non-haemocompatibility-related events [adjusted RR 0.90

......................................................................................................

a malfunctioning pump and (B) overall survival between the pivotal and continued access protocol (CAP) cohorts. CI, confidence interval; HR,
hazard ratio. *Adjusted HRs and P-values are calculated with Cox regression. HRs are presented for CAP vs. pivotal cohorts and adjusted
for age, sex, race (Caucasian or non-Caucasian), intended use (bridge to transplant or candidacy, or destination therapy), and INTERMACS
profile (1–3 or 4–7).

(95% CI 0.84–0.96), P < 0.001] and indicated no significant
effect.
The 2-year rates for the individual adverse events are shown in
Table 2. In the CAP cohort, suspected pump thrombosis remained
a rare event (1.1%). At 2 years post-implant, freedom from stroke
was 89.6% for CAP and 88.6% for the pivotal cohort (online
supplementary Figure S4). For bleeding, rates were not significantly
different between cohorts for gastrointestinal bleeding [adjusted
RR 1.07 (95% CI 0.93–1.24), P = 0.33] or events requiring surgery
[adjusted RR 1.16 (95% CI 0.88–1.55), P = 0.29].
Several adverse events demonstrated significant improvements
from the pivotal trial to CAP. Infection, specifically localized infections, and cardiac arrhythmias were lower in CAP. Overall right
heart failure event rates were similar between cohorts; however,
events requiring RVAD placement were more frequent in CAP
[adjusted RR 1.68 (95% CI 1.06–2.68), P = 0.028]. In both cohorts,
over 90% of the RVADs were placed within 30 days of the HM3
implant (online supplementary Figure S5).
The pooled cohort was used to identify independent predictors of right heart failure requiring RVAD placement. Covariates
included baseline variables such as age, sex, race, intended use,
INTERMACS profile, IABP use, and study cohort (CAP or pivotal). Parameters associated with right heart function were also
considered (central venous pressure/pulmonary capillary wedge
pressure ratio, pulmonary artery pulsatility index, right ventricular stroke work index, estimated glomerular filtration rate (eGFR),
total bilirubin, and moderate/severe tricuspid valve regurgitation).
The final predictors in the multivariate logistic regression model
are shown in online supplementary Table S1. IABP use, transplant ineligibility (DT), INTERMACS profiles 1–2, and lower eGFR
were independently associated with a higher likelihood of RVAD
requirement. Overall survival in patients requiring RVAD was
lower than in those without RVAD use (online supplementary
Figure S6).

© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Overall survival by intended goal of implant. Comparison of survival between pivotal and continued access protocol (CAP) cohorts
in (A) bridge to transplant or candidacy (BTT/BTC) and (B) destination therapy (DT) patients. CI, confidence interval; HR, hazard ratio.
*Adjusted HRs and P-values are calculated with Cox regression. HRs are presented for CAP vs. pivotal cohorts and adjusted for age, sex, race
(Caucasian or non-Caucasian), and INTERMACS profile (1–3 or 4–7).

Figure 3 Impact of clinical severity on outcomes. Comparison of (A) the composite endpoint and (B) overall survival between INTERMACS

Hospitalizations
In the pivotal cohort, 94.2% of patients (485/515) were discharged
from the implant hospitalization on HM3 support with a median
length of stay of 19 days (Q1–Q3: 14–25). Similarly, 93.2% of CAP
patients (1571/1685) were discharged with a median length of stay
of 19 days (Q1–Q3: 14–26, P = 0.74). The all-cause readmission
rate was lower in CAP compared to the pivotal trial [2.03 vs. 2.26
EPPY; adjusted RR 0.90 (95% CI 0.86–0.96), P < 0.001].

Discussion
In this primary results report of the MOMENTUM 3 trial portfolio including the pivotal and CAP phase, we present the principal

.........................................

profiles 1–2 (‘unstable’ advanced heart failure), profile 3 (‘stable’ on inotropic therapy) and profiles 4–7 (‘stable’ ambulatory advanced heart
failure). CI, confidence interval; HR, hazard ratio. *Adjusted HRs and P-values are calculated with Cox regression. HRs are presented for profiles
3 vs. 1–2 and profiles 4–7 vs. 1–2 and adjusted for age, sex, race (Caucasian or non-Caucasian), and intended use (bridge to transplant or
candidacy, or destination therapy).

2-year clinical outcomes in the largest reported prospective series
of 2200 consecutively enrolled patients implanted with the HM3
LVAD. The main findings include the following: (i) survival with
the HM3 LVAD approaches or exceeds 80% at 2 years, irrespective of clinical severity of advanced heart failure at the time of
pump implantation; (ii) outcomes by intended goal of implant based
on transplant ineligibility (BTT/BTC or DT) are similar between
the pivotal and CAP cohorts, and specifically, survival of transplant ineligible patients is comparable to that reported with heart
transplantation14 ; (iii) evidence of improving clinical experience is
noted by a lower ‘net burden’ of adverse events in the post-pivotal
trial cohort, principally driven by non-haemocompatibility-related
events, such as infection; and (iv) all-cause hospitalizations are
fewer in the CAP cohort (Graphical Abstract).

© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 4 Net burden of adverse events. Comparison of the adverse event burden between the pivotal and continued access protocol (CAP)
cohorts. CI, confidence interval; EPPY, events per patient-year. *Adjusted rate ratios and P-values are calculated with Poisson regression.
Rate ratios are presented for CAP vs. pivotal cohorts and adjusted for age, sex, race (Caucasian or non-Caucasian), intended use (bridge to
transplant or candidacy, or destination therapy), and INTERMACS profile (1–3 or 4–7).

Table 2 Comparison of adverse events between the pivotal and continued access protocol cohorts
Adverse event

Pivotal cohort
(n = 515)

CAP cohort
(n = 1685)

Pivotal cohort
CAP cohort
Adjusted rate
P-value*
(n = 515)
(n = 1685)
ratio (95% CI)*
EPPY
EPPY
...........................................................................................................................................
Suspected pump thrombosis
Any stroke
Haemorrhagic
Ischaemic
Disabling
Any bleeding
Gastrointestinal
Requiring surgery
Any major infection
Driveline
Sepsis
Localized
Any right heart failure
Requiring RVAD
Cardiac arrhythmia
Supraventricular
Ventricular
Respiratory failure
Renal dysfunction

7 (1.4%)
51 (9.9%)
25 (4.9%)
29 (5.6%)
26 (5.0%)
225 (43.7%)
126 (24.5%)
50 (9.7%)
300 (58.3%)
120 (23.3%)
78 (15.1%)
210 (40.8%)
176 (34.2%)
21 (4.1%)
185 (35.9%)
97 (18.8%)
107 (20.8%)
111 (21.6%)
73 (14.2%)

18 (1.1%)
153 (9.1%)
74 (4.4%)
87 (5.2%)
73 (4.3%)
844 (50.1%)
488 (29.0%)
225 (13.4%)
968 (57.4%)
390 (23.1%)
259 (15.4%)
620 (36.8%)
630 (37.4%)
125 (7.4%)
568 (33.7%)
278 (16.5%)
314 (18.6%)
334 (19.8%)
251 (14.9%)

0.01
0.08
0.03
0.04
0.04
0.61
0.31
0.08
0.82
0.23
0.13
0.46
0.27
0.03
0.37
0.15
0.20
0.19
0.11

0.01
0.07
0.03
0.04
0.03
0.71
0.36
0.10
0.73
0.21
0.13
0.39
0.27
0.05
0.30
0.12
0.17
0.16
0.11

0.74 (0.31–1.81)
0.86 (0.63–1.16)
0.86 (0.55–1.35)
0.86 (0.57–1.29)
0.76 (0.50–1.17)
1.09 (0.99–1.21)
1.07 (0.93–1.24)
1.16 (0.88–1.55)
0.86 (0.79–0.94)
0.92 (0.77–1.09)
0.92 (0.74–1.15)
0.83 (0.73–0.94)
1.03 (0.88–1.20)
1.68 (1.06–2.68)
0.82 (0.71–0.94)
0.76 (0.61–0.95)
0.85 (0.71–1.03)
0.83 (0.69–1.01)
0.87 (0.68–1.11)

0.51
0.32
0.51
0.45
0.21
0.09
0.33
0.29
0.001
0.32
0.48
0.003
0.73
0.028
0.004
0.014
0.09
0.06
0.27

The MOMENTUM 3 trial, which in its pivotal phase was the
largest randomized trial of LVAD therapy, extended its experience
with the HM3 pump during the post-pivotal trial phase by enrolling
three times more HM3 LVAD patients as in the pivotal trial.
The post-pivotal trial cohort applied the same rigor in outcomes

...............

CAP, continued access protocol; CI, confidence interval; EPPY, events per patient-year; RVAD, right ventricular assist device.
*Adjusted rate ratios and P-values are calculated with Poisson regression. Rate ratios are presented for CAP vs. pivotal cohorts and are adjusted for age, sex, race (Caucasian
or non-Caucasian), intended use (bridge to transplant or candidacy, or destination therapy), and INTERMACS profile (1–3 or 4–7).

assessment as in the pivotal trial phase among the same centres,
allowing for adequate between-group comparisons. This analysis
replicates the gains in clinical outcomes reported during the pivotal
trial and extends observations to clinically important sub-groups
that did not have sufficient sample sizes for assessment in the early
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trial experience. For example, by pooling the pivotal and CAP
cohorts, we can now analyse 753 patients categorized as ‘unstable’
advanced heart failure in INTERMACS 1–2 profiles.15 Although
‘unstable’ INTERMACS profile 1–2 patients demonstrate slightly
lower survival when compared with the more stable INTERMACS
3 profile (who also require inotropic therapy), the composite
primary endpoint is similar across the severity subsets. These data
provide confidence that the HM3 pump performs well throughout
the continuum of clinical severity when patients are recruited based
upon the inclusion and exclusion criteria of the trial portfolio.
Thus, these findings also provide guidance for appropriate selection
of patients across a broad range of clinical presentations with
predictable principal clinical outcomes.
Generally, advanced heart failure patients tend to segregate
among those that are transplant ineligible (DT) or those eligible
or possibly convertible into eligible patients for transplantation.
Prior studies enforced such a dichotomy and reduced confidence
in outcomes with those deemed transplant ineligible due to observations of lower survival in such patient cohorts.16,17 The advent of
the HM3 pump has led to greater confidence in LVAD use among
transplant ineligible patients such that even regulatory authorities
in the United States have abandoned the use of such terminology
in preference for a single indication of use in patients refractory
to pharmacological disease-modifying therapy.17,18 We now introduce further certainty that transplant ineligible patients experience
excellent survival comparable to rates noted with heart transplantation, at least in the 2-year observation period.14 Several countries
still do not endorse the notion of LVAD implantation beyond a
transplant bridge and we believe that reconsideration of this stance
is necessary, as many now advocate.19 Another real-world experience among advanced heart failure patients who are beneficiaries
of governmental health insurance and proportionately less eligible
for transplantation, has shown a survival advantage to HM3 LVAD
use when compared with other commercial LVADs.20
The HM3 LVADs were specifically designed to reduce
haemocompatibility-related adverse events including pump
thrombosis, strokes and bleeding.11 The pivotal trial phase of
MOMENTUM 3 confirmed superiority of the HM3 pump in these
domains but non-haemocompatibility-related adverse events were
largely unaltered.4 The post-pivotal trial experience replicates
the benefits regarding haemocompatibility-related adverse events
and extends those gains to additional adverse events particularly
infections, which have been noted to cumulatively be the most
common adverse event encountered during the LVAD patient
journey.4 A recent analysis of infections in HM3 patients reported
that local infections unrelated to pump components were most
common followed by driveline-associated infection, suggesting
that circulatory changes may confer an immunomodulatory effect
predisposing to infection.21 The finding of reduced infections
suggests that closer attention to LVAD patient care and better
surveillance may contribute to ameliorating this adverse event.
These observations endorse the importance of effective patient
and care provider education as well as multidisciplinary ambulatory
care.22 We observed an increased early RVAD requirement in
the post-pivotal trial cohort despite similar rates of right heart
failure over time. Our multivariable analysis demonstrates that this

........................................................................................................................................................................
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reflects the sicker population enrolled and greater preponderance
of transplant ineligible patients, a population likely to experience
earlier haemodynamic instability.23,24 It is not easy to predict the
need for RVAD support using haemodynamic parameters or other
metabolic indices and the clearest risk for such use is based on
the overall clinical severity at time of implantation.25
We recognize that 2-year outcomes may not be sufficient and
longer-term follow up is desirable. The MOMENTUM 3 pivotal
trial phase has been extended to study 5-year outcomes, even
as other smaller multicentre reports surface with longer-term
outcomes.26 As we explore longer-term outcomes, we need to
stay vigilant for complications that may result from degeneration
of peripheral pump components. A rare complication of outflow
graft compression has been recognized in some late survivors
of LVAD implantation that presents with a decrease in pump
flow.27 Continuous reduction of the adverse event burden will be
necessary to improve the patient journey and experience in the
longer term. Trials to evaluate reduced exposure to anticoagulation
regimens or to avoid the use of aspirin are ongoing in an effort
to further control bleeding events.28,29 Efforts to fully internalize
the LVAD system and reduce driveline infections are being actively
pursued.1 These advances are required to improve the overall
cost-effectiveness of LVAD therapy with the HM3 pump, especially
if this therapy is deemed to replace an established option such as
heart transplantation.20,30
In conclusion, accumulating post-pivotal trial experience with
the HM3 LVAD suggests a lower adverse event burden, reduced
hospitalizations and similar survival free of disabling stroke or reoperation to replace or remove a malfunctioning pump as compared
to the pivotal MOMENTUM 3 trial outcomes at 2 years. These
beneficial outcomes were noted across the continuum of clinical
severity in advanced heart failure and especially among transplant
ineligible patients in whom outcomes may now compare favourably
with those in transplant eligible patients at 2 years.

Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
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